Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis,…

Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point

The solution missed the primary end point of the trial, which was complete resolution of debris after 6 weeks of twice-daily dosing.

Viatris’ ophthalmic drug flunks Phase 3 study, company mulls next steps

Viatris said Friday its treatment candidate for a common form of eye inflammation failed a late-stage trial, casting uncertainty on the program’s future. The biotech’s pimecrolimus 0.3% ointment did not meet the Phase 3 primary ...

Update On Phase 3 MR-139 Study For Blepharitis

The MR-139 3001 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks.